Can a cheaper copy of a leukemia drug work just as well?
NCT ID NCT07723911
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a new drug called BLB101 works as well as the approved drug Blincyto for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The study will compare how the drugs are processed in the body, how well they control the cancer, and their side effects. About 212 participants will receive either BLB101 or Blincyto over two 6-week treatment cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a biosimilar drug called BLB101, compared to the approved drug blinatumomab (Blincyto)
- What this could lead to
- If BLB101 proves similar to Blincyto in effectiveness and safety, it could offer an additional treatment option for adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
- What could go wrong
- This is a phase 3 trial, but the drug is a biosimilar, so small differences in manufacturing could affect outcomes. The trial is also limited to a specific patient population, and results may not apply to all leukemia patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at tough childhood cancers
- Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse
- Off-the-Shelf CAR-T cells take on tough leukemia in early trial
- New CAR t-cell combo aims to control aggressive leukemia
- Simpler CAR-T therapy tested for tough blood cancers
- New hope for tough leukemia: CAR t cell trial opens for adults